FDA Approves Additional Indication For Norditropin(R) For Small For Gestational Age (SGA) In Children

Children born with a condition that can prevent them from growing to a normal height now have a new treatment option available with the approval of Norditropin(R) (somatropin [rDNA origin] injection) for the treatment of short stature in children born Small for Gestational Age (SGA) with no catch-up growth by age 2-4 years. The U.S. Food and Drug Administration (FDA) approved Norditropin(R) based on data from a 13-year clinical trial in children SGA.

More: continued here

Filed under: Endocrinology on November 7th, 2008